Extendicare Inc. (TSE:EXE - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is C$14.92.
Several research firms recently weighed in on EXE. CIBC set a C$18.00 price objective on shares of Extendicare and gave the stock an "outperform" rating in a report on Monday, September 22nd. National Bank Financial raised shares of Extendicare to a "strong-buy" rating in a research note on Wednesday, July 16th. Cibc World Mkts upgraded Extendicare to a "strong-buy" rating in a research report on Monday, September 22nd. Finally, National Bankshares upped their target price on Extendicare from C$15.45 to C$16.10 and gave the stock an "outperform" rating in a research report on Friday, August 8th.
Read Our Latest Stock Report on EXE
Extendicare Trading Down 1.7%
Shares of EXE stock opened at C$14.87 on Wednesday. The company has a debt-to-equity ratio of 283.02, a quick ratio of 0.98 and a current ratio of 0.62. Extendicare has a 1 year low of C$8.96 and a 1 year high of C$15.24. The stock has a fifty day moving average of C$13.23 and a two-hundred day moving average of C$13.52. The firm has a market capitalization of C$1.25 billion, a PE ratio of 15.41 and a beta of 0.85.
Extendicare Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Monday, September 15th were given a dividend of $0.042 per share. This represents a $0.17 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Friday, August 29th. Extendicare's dividend payout ratio is 50.57%.
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.